Moreover, transthyretin protein silencers such as patisiran and inotersen have shown promising outcomes in the treatment of ATTR-CA and are currently approved by the American Food and Drug Administration (FDA) for the treatment of hereditary ATTR with concurrent neuropathy (3). The gene discussed is TTR; the disease is neuropathy.